Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
303 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | terminated | Phase 3 | 766 | BayerINDUSTRY | 23 | Oct 18, 2024 | clinicaltrials |
| NCT03859427 | A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma(ARROW2) | completed | Phase 3 | 454 | AmgenINDUSTRY | 17 | Aug 13, 2024 |
| clinicaltrials |
| NCT03306394 | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).(PRECONNECT) | completed | Phase 3 | 907 | Institut de Recherches Internationales ServierOTHER | 16 | Jul 25, 2024 | clinicaltrials |
| NCT01231347 | QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas(GAMMA) | completed | Phase 3 | 800 | NantCell, Inc.INDUSTRY | 32 | Jul 16, 2024 | clinicaltrials |
| NCT02928406 | A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract | completed | Phase 3 | 1,004 | Hoffmann-La RocheINDUSTRY | 32 | Apr 4, 2024 | clinicaltrials |
| NCT03125902 | A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)(IMpassion131) | completed | Phase 3 | 653 | Hoffmann-La RocheINDUSTRY | 24 | Mar 26, 2024 | clinicaltrials |
| NCT01288378 | Empirical Versus Preemptive Antifungal Therapy | completed | Phase 3 | 556 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Dec 11, 2023 | clinicaltrials |
| NCT02941926 | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC(COMPLEEMENT-1) | completed | Phase 3 | 3,246 | Novartis PharmaceuticalsINDUSTRY | 38 | Oct 24, 2023 | clinicaltrials |
| NCT02125461 | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer(PACIFIC) | completed | Phase 3 | 713 | AstraZenecaINDUSTRY | 26 | Oct 10, 2023 | clinicaltrials |
| NCT03826628 | Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex | completed | Phase 2 / Phase 3 | 107 | Dermatology Specialties Limited PartnershipINDUSTRY | 9 | Sep 8, 2023 | clinicaltrials |
| NCT03185013 | REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)(REVEAL 1) | completed | Phase 3 | 201 | Inovio PharmaceuticalsINDUSTRY | 19 | Jul 27, 2023 | clinicaltrials |
| NCT02609828 | Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy | completed | Phase 3 | 156 | PfizerINDUSTRY | 16 | Feb 16, 2023 | clinicaltrials |
| NCT02819960 | Prevention of Irinotecan Induced Diarrhea by Probiotics | completed | Phase 3 | 233 | S&D Pharma SK s.r.o.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT01568866 | Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients(ENDEAVOR) | completed | Phase 3 | 929 | AmgenINDUSTRY | 27 | Nov 14, 2022 | clinicaltrials |
| NCT01345019 | Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma | completed | Phase 3 | 1,718 | AmgenINDUSTRY | 29 | Nov 8, 2022 | clinicaltrials |
| NCT00842348 | Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour(NET729) | completed | Phase 3 | 89 | IpsenINDUSTRY | 9 | Oct 12, 2022 | clinicaltrials |
| NCT03410693 | Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma(FORT-1) | completed | Phase 2 / Phase 3 | 175 | BayerINDUSTRY | 29 | Sep 28, 2022 | clinicaltrials |
| NCT01001377 | ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | completed | Phase 3 | 1,010 | AmgenINDUSTRY | 29 | Sep 21, 2022 | clinicaltrials |
| NCT02793583 | Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma(UNITY-NHL) | terminated | Phase 2 / Phase 3 | 710 | TG Therapeutics, Inc.INDUSTRY | 9 | Jul 21, 2022 | clinicaltrials |
| NCT02663908 | A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease(PRONOUNCE) | terminated | Phase 3 | 545 | Ferring PharmaceuticalsINDUSTRY | 12 | Jun 29, 2022 | clinicaltrials |
| NCT02200614 | Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer(ARAMIS) | completed | Phase 3 | 1,509 | BayerINDUSTRY | 36 | Jun 28, 2022 | clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT02472964 | Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.(HERiTAge) | completed | Phase 3 | 500 | Mylan Inc.INDUSTRY | 15 | Feb 14, 2022 | clinicaltrials |
| NCT03085095 | A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer(HERO) | completed | Phase 3 | 1,134 | Myovant Sciences GmbHINDUSTRY | 22 | Jan 18, 2022 | clinicaltrials |
| NCT00982111 | First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin(INSPIRE) | completed | Phase 3 | 633 | Eli Lilly and CompanyINDUSTRY | 20 | Jan 11, 2022 | clinicaltrials |
| NCT01712789 | Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma(STRATUS) | completed | Phase 3 | 682 | CelgeneINDUSTRY | 20 | Jan 10, 2022 | clinicaltrials |
| NCT00703326 | Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer | completed | Phase 3 | 1,144 | Eli Lilly and CompanyINDUSTRY | 23 | Dec 6, 2021 | clinicaltrials |
| NCT02551159 | Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer(KESTREL) | completed | Phase 3 | 823 | AstraZenecaINDUSTRY | 23 | Oct 13, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT02366143 | A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)(IMpower150) | completed | Phase 3 | 1,202 | Hoffmann-La RocheINDUSTRY | 26 | Sep 23, 2021 | clinicaltrials |
| NCT02165215 | A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors(LAUREL) | completed | Phase 3 | 359 | Hoffmann-La RocheINDUSTRY | 15 | Aug 19, 2021 | clinicaltrials |
| NCT01524783 | Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)(RADIANT-4) | completed | Phase 3 | 302 | Novartis PharmaceuticalsINDUSTRY | 25 | Aug 5, 2021 | clinicaltrials |
| NCT02163759 | A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors(HIBISCUS I) | completed | Phase 3 | 358 | Hoffmann-La RocheINDUSTRY | 14 | Jul 23, 2021 | clinicaltrials |
| NCT01743989 | A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.(ENESTPath) | completed | Phase 3 | 620 | Novartis PharmaceuticalsINDUSTRY | 21 | Jul 15, 2021 | clinicaltrials |
| NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer(CORAL) | terminated | Phase 3 | 200 | Tris Pharma, Inc.INDUSTRY | 14 | Jul 15, 2021 | clinicaltrials |
| NCT02031432 | CORAL XT - Open-label Extension Trial of the CORAL Trial(CORAL XT) | completed | Phase 3 | 76 | Tris Pharma, Inc.INDUSTRY | 10 | Jul 15, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT02093663 | Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis(PACE) | completed | Phase 3 | 107 | ShireINDUSTRY | 7 | Jun 9, 2021 | clinicaltrials |
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.(CONTI-PV) | completed | Phase 3 | 170 | AOP Orphan Pharmaceuticals AGINDUSTRY | 12 | Jun 1, 2021 | clinicaltrials |
| NCT02130557 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 3 | 536 | PfizerINDUSTRY | 26 | May 18, 2021 | clinicaltrials |
| NCT01566721 | A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer(SafeHER) | completed | Phase 3 | 2,577 | Hoffmann-La RocheINDUSTRY | 59 | Apr 27, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT01763164 | Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma | completed | Phase 3 | 402 | PfizerINDUSTRY | 27 | Mar 22, 2021 | clinicaltrials |
| NCT00585312 | Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)(CHIP) | terminated | Phase 3 | 106 | Pfizer's Upjohn has merged with Mylan to form Viatris Inc.INDUSTRY | 14 | Feb 21, 2021 | clinicaltrials |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 3 | 475 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 15, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials